Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

MERTK Antikörper (Extracellular, N-Term) (FITC)

Der Kaninchen Polyklonal anti-MERTK Antikörper wird verwendet zum Nachweis von MERTK in Proben von Maus. Er wurde validiert für FACS und LCI.
Produktnummer ABIN7237599
854,77 €
Zzgl. Versandkosten 20,00 € und MwSt
Lieferung nach: Deutschland
Lieferung in 8 bis 9 Werktagen

Kurzübersicht für MERTK Antikörper (Extracellular, N-Term) (FITC) (ABIN7237599)

Target

Alle MERTK Antikörper anzeigen
MERTK (C-Mer Proto-Oncogene Tyrosine Kinase (MERTK))

Reaktivität

  • 129
  • 46
  • 32
  • 5
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Maus

Wirt

  • 95
  • 38
  • 4
  • 3
  • 2
Kaninchen

Klonalität

  • 76
  • 66
Polyklonal

Konjugat

  • 80
  • 11
  • 5
  • 4
  • 4
  • 4
  • 4
  • 4
  • 4
  • 3
  • 3
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Dieser MERTK Antikörper ist konjugiert mit FITC

Applikation

  • 80
  • 67
  • 52
  • 21
  • 20
  • 19
  • 17
  • 13
  • 9
  • 9
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Flow Cytometry (FACS), Live Cell Imaging (LCI)
  • Bindungsspezifität

    • 22
    • 13
    • 9
    • 9
    • 8
    • 6
    • 4
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 402-416, Extracellular, N-Term

    Verwendungszweck

    A Rabbit Polyclonal Antibody to MERTK (extracellular) conjugated to the fluorescent dye FITC

    Kreuzreaktivität

    Human, Maus, Ratte

    Homologie

    Rat - identical, human - 13,15 amino acid residues identical

    Produktmerkmale

    Extracellular, N-terminus

    Aufreinigung

    Affinity purified on immobilized antigen.

    Immunogen

    (C)KPPIKRQDGELVGYR, corresponding to amino acid residues 402 - 416 of mouse MERTK 

    Isotyp

    IgG
  • Applikationshinweise

    WB: The optimal concentration should be determined by the user

    FC: 2.5-5 mg per reaction

    ICC: The optimal concentration should be determined by the user

    IHC: The optimal concentration should be determined by the user

    IP: The optimal concentration should be determined by the user

    Kommentare

    Negative Control: (ABIN7582044)

    Blocking Peptide: (ABIN7234888)

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    15 μL or 50 μL double distilled water (DDW), depending on the sample size.

    Konzentration

    1 mg/mL

    Buffer

    PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

    Konservierungsmittel

    Sodium azide

    Vorsichtsmaßnahmen

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Lagerung

    -20 °C

    Informationen zur Lagerung

    The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C
  • Target

    MERTK (C-Mer Proto-Oncogene Tyrosine Kinase (MERTK))

    Andere Bezeichnung

    MERTK

    Hintergrund

    Synonyms: Receptor tyrosine kinase MerTK, C-Mer Proto-Oncogene Tyrosine Kinase, Mer, Proto-Oncogene C-Mer

    Description: Myeloid-epithelial-reproductive tyrosine kinase, MERTK, is a receptor tyrosine kinase of the TAM (Tyro3, Axl and MERTK) family, expressed in numerous cancers1.The extracellular N-terminal domain contains two immunoglobulin-like and two fibronectin 3 domains, followed by a hydrophobic single pass transmembrane domain, and a cytoplasmic C-terminal tail containing a tyrosine kinase domain1,2.Auto-phosphorylation induced by ligand binding influences a range of downstream signaling pathways and cellular functions2. The physiological roles of MERTK include regulation of tissue homeostasis and repair, innate immune control, and platelet aggregation. However, aberrant expression of this protein promotes neoplasia, cell cycle progression, proliferation and tumor growth, resistance to apoptosis, and promotion of tumor metastases.MERTK is involved in the activation of several canonic oncogenic signaling pathways in various types of cancers including: leukemia, non-small cell lung cancer, glioblastoma, melanoma, prostate cancer, breast cancer, colon cancer and gastric cancer1,3,4.Due to its pivotal role in cancer development and metastasis, multiple therapeutic approaches are currently in development to inhibit MERTK, including ligand "traps" and small-molecule tyrosine kinase inhibitors4.

    Gen-ID

    17289

    NCBI Accession

    NM_006343

    UniProt

    Q60805

    Pathways

    RTK Signalweg
Sie sind hier:
Chat with us!